Join us as Lawrence Sherman speaks with Dr. Andrew Chan on the utility of NEDA-3 and NEDA-4 in MS treatment, as well as other considerations to improve MS treatment monitoring and the potential role of cladribine in the management of MS.
This interview was conducted while at the Multiple sclerosis: meeting unmet needs through scientific discoveries and clinical practice conference. This international conference was conducted by one of our partners, EXCEMED.
As of August 2018, Cladribine was approved in Europe for the treatment of highly active relapsing multiple sclerosis (RMS). All studies presented in this education are still accurate. To learn more about this approval, click here.